• LAST PRICE
    0.6002
  • TODAY'S CHANGE (%)
    Trending Up0.0124 (2.1096%)
  • Bid / Lots
    0.6001/ 1
  • Ask / Lots
    0.6060/ 21
  • Open / Previous Close
    0.6000 / 0.5878
  • Day Range
    Low 0.5851
    High 0.6100
  • 52 Week Range
    Low 0.3650
    High 0.9650
  • Volume
    296,205
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.5878
TimeVolumeSESN
09:32 ET43150.5851
09:35 ET37000.585607
09:37 ET132500.5937
09:42 ET303000.5887
09:44 ET251000.5861
09:46 ET7000.5929
09:50 ET201000.5999
09:53 ET1000.5944
09:55 ET50000.593
09:57 ET264250.593
10:00 ET127260.593
10:06 ET1000.5976
10:08 ET58020.595
10:11 ET1560.599899
10:13 ET207000.5975
10:15 ET1000.595
10:20 ET95450.5974
10:22 ET141000.5999
10:24 ET86250.5931
10:26 ET1000.59655
10:31 ET1000.5931
10:36 ET1000.5975
10:38 ET62000.599
10:40 ET2000.6
10:42 ET9180.599
10:44 ET11160.5999
10:45 ET102280.5982
10:47 ET20800.6098
10:49 ET5000.6095
10:51 ET152250.6
10:54 ET7000.6094
10:56 ET23000.60475
10:58 ET3000.6094
11:00 ET14420.6013
11:02 ET3000.61
11:03 ET413500.6099
11:05 ET4000.606
11:07 ET70000.6001
11:09 ET6000.6002
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSESN
Sesen Bio Inc
119.2M
-35.5x
---
United StatesMDXH
MDxHealth SA
114.2M
0.0x
---
United StatesSYRS
Syros Pharmaceuticals Inc
103.6M
-0.3x
---
United StatesSLGL
Sol Gel Technologies Ltd
129.0M
30.1x
---
United StatesFSTX
F-Star Therapeutics Inc
107.7M
-2.4x
---
United StatesCELU
Celularity Inc
135.2M
-5.6x
---
As of 2023-02-03

Company Information

Sesen Bio, Inc. is a late-stage clinical company engaged in advancing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer. The Company's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. The Company’s advanced product candidate Vicinium, also known as VB4-845, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus calmette-guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).

Contact Information

Headquarters
245 1st St Ste 1800CAMBRIDGE, MA, United States 02142-1292
Phone
617-444-8550
Fax
617-858-0911

Executives

Independent Chairman of the Board
Jay Duker
President, Chief Executive Officer, Director
Thomas Cannell
Chief Financial Officer, Treasurer
Monica Forbes
Chief Technology Officer
Glen MacDonald
Chief Accounting Officer, Controller
Elly Ryu

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$119.2M
Revenue (TTM)
$60.0M
Shares Outstanding
202.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.82
EPS
$-0.02
Book Value
$0.86
P/E Ratio
-35.5x
Price/Sales (TTM)
2.0
Price/Cash Flow (TTM)
---
Operating Margin
-13.49%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.